Our News on Newswise

Cancer Research Institute to Host Annual Virtual Immunotherapy Patient Summit on November 11-12, 2022

Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
26-Oct-2022 2:45 PM EDT Add to Favorites

Cancer Research Institute and Israel Cancer Research Fund Announce Co-Funding of a Translational Immunotherapy Research Grant

The CRI-ICRF Clinic and Laboratory Integration Program (CLIP) Grant to Fund Promising Immunotherapy Research in Israel Is Awarded to Yifat Merbl, PhD, of the Weizmann Institute of Science.
11-Oct-2022 8:00 AM EDT Add to Favorites

Cancer Research Institute to Honor Scientists for Groundbreaking Discoveries Leading to New Immune-Based Strategies That Target Gasdermins in Cancer Treatment

The Cancer Research Institute (CRI), a nonprofit organization dedicated to harnessing the immune system’s power to control and potentially cure all types of cancer, will confer its prestigious 2022 William B. Coley Award for Distinguished Research...
30-Sep-2022 6:05 PM EDT Add to Favorites

El Cancer Research Institute Presentará La Segunda Conferencia Virtual en Español Cri De Inmunoterapia Para Pacientes Con Cáncer, Moderada Por Ana Patricia Gámez, Quien Compartirá Información Vital Para La Comunidad Hispana, Pacientes Y Sus Familias

El Cancer Research Institute (CRI), una organización sin fines de lucro consagrada a aprovechar la capacidad del sistema inmunitario para combatir y potencialmente curar todos los tipos de cáncer, ofrecerá su segunda Conferencia Virtual CRI de...
6-Sep-2022 4:45 PM EDT Add to Favorites

Cancer Research Institute to Host Second-Annual Spanish-Language Virtual Immunotherapy Patient Summit, Moderated by Ana Patricia Gámez, to Connect the U.S. Hispanic Cancer Community with Information That Can Save Lives

The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system’s power to control and potentially cure all cancers, will offer its second annual CRI Virtual Immunotherapy Patient...
6-Sep-2022 4:45 PM EDT Add to Favorites

Cancer Research Institute Names Newest Class of Lloyd J. Old STARs, Today’s Visionaries in Cancer Immunotherapy Research

Six U.S. scientists have been awarded $1.25 million each over 5 years to conduct high-risk, high-reward cancer immunology research with the potential to transform cancer treatment
22-Jun-2022 1:20 PM EDT Add to Favorites

Cellular Cancer Immunotherapy Clinical Development Continues to Evolve and Expand with Novel Technologies and Targets, New Report From Cancer Research Institute Shows

Latest analysis from the Cancer Research Institute of the global landscape of cellular immunotherapies, including R&D trends and real-world usage, highlights key challenges including effective solid tumor targeting, manufacturing complexities, and...
1-Jun-2022 10:05 AM EDT Add to Favorites

Cancer Research Institute Hosts 10th Annual Cancer Immunotherapy Month™ Celebrating Lifesaving Discovery in Immuno-Oncology

Global celebration of 10 years of discovery and lifesaving innovation in immuno-oncology
27-May-2022 2:35 PM EDT Add to Favorites

See All News

Our Experts on Newswise

Expert Available for Commentary on Recent FDA Analysis of TNF Blockers

The FDA announced on Aug 4 2009 that tumor necrosis factor (TNF) blockers used in the treatment of immune disorders carry an increased risk of lymphoma and other cancers in children and adolescents. The discoverer of TNF-alpha, Lloyd J. Old, M.D., a...
7-Aug-2009 9:00 AM EDT

PROVENGE Cancer Vaccine Heralds New Dawn in Cancer Therapy

Dendreon's PROVENGE for the treatment of advanced prostate cancer is the first active cellular immunotherapy to prolong patient survival, according to data from a pivotal phase III clinical trial announced at yesterday's AUA annual meeting in...
29-Apr-2009 11:20 AM EDT

See All Experts

Our YouTube Videos


The mission of the Cancer Research Institute is to save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.


Brian Brewer
Chief Communications Officer


212-688-7515 x242